Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 354

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer

Open access
Sinn, Bruno V., Fu, Chunxiao, Lau, Rosanna, Litton, Jennifer, Tsai, Tsung-Heng, Murthy, Rashmi, Tam, Alda, Andreopoulou, Eleni, Gong, Yun, Murthy, Ravi, Gould, Rebekah, Zhang, Ya, King, Tari A., Viale, Agnes, Andrade, Victor, Giri, Dilip, Salgado, Roberto, Laios, Ioanna, Sotiriou, Christos, Marginean, Esmeralda C., Kwiatkowski, Danielle N., Layman, Rachel M., Booser, Daniel, Hatzis, Christos, Vicente Valero, V., Fraser Symmans, W. · 2019 · npj Breast Cancer

Abstract

There is a clinical need to predict sensitivity of metastatic hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer to endocrine therapy, and targeted RNA sequencing (RNAseq) offers diagnostic potential to measure both transcriptional activity and functional mutation. We developed the SET ER/PR index to measure gene expression microarray probe sets that were correlated with hormone receptors (ESR1 and PGR) and robust to preanalytical and analytical influences. We tested SET ER/PR index in biopsies of metastastic HR+/HER2− breast cancer against the treatment outcomes in 140 patients. Then we customized the SET ER/PR assay to measure 18 informative, 10 reference transcripts, and sequence the ligand-binding domain (LBD) of ESR1 using droplet-based targeted RNAseq, and tested that in residual RNA from 53 patients. Higher SET ER/PR index in metastatic samples predicted longer PFS and OS when patients received endocrine therapy as next treatment, even after adjustment for clinical-pathologic risk factors (PFS: HR 0.534, 95% CI 0.299 to 0.955, p = 0.035; OS: HR 0.315, 95% CI 0.157 to 0.631, p = 0.001). Mutated ESR1 LBD was detected in 8/53 (15%) of metastases, involving 1−98% of ESR1 transcripts (all had high SET ER/PR index). A signature based on probe sets with good preanalytical and analytical performance facilitated our customization of an accurate targeted RNAseq assay to measure both phenotype and genotype of ER-related transcription. Elevated SET ER/PR was associated with prolonged sensitivity to endocrine therapy in patients with metastatic HR+/HER2− breast cancer, especially in the absence of mutated ESR1 transcript.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41523-019-0111-0

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 354

Metadata

Authors
Sinn, B. V., Fu, C., Lau, R., Litton, J., Tsai, T.-H., Murthy, R., Tam, A., Andreopoulou, E., Gong, Y., Murthy, R., Gould, R., Zhang, Y., King, T. A., Viale, A., Andrade, V., Giri, D., Salgado, R., Laios, I., Sotiriou, C., Marginean, E. C., Kwiatkowski, D. N., Layman, R. M., Booser, D., Hatzis, C., Vicente Valero, V., & Fraser Symmans, W.
Venue
npj Breast Cancer
Published
2019-05-30
Volume
5
Issue
1
Pages
16-16
ISSN
2374-4677 (ISSN-L)
OpenAlex
W2947470150
Cited by
354
References
31
FWCI
21.01
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. https://app.cochat.ai/papers/10.1038/s41523-019-0111-0
The paper
Sinn, B. V., Fu, C., Lau, R., Litton, J., Tsai, T.-H., Murthy, R., Tam, A., Andreopoulou, E., Gong, Y., Murthy, R., Gould, R., Zhang, Y., King, T. A., Viale, A., Andrade, V., Giri, D., Salgado, R., Laios, I., Sotiriou, C., . . . Fraser Symmans, W. (2019). SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. npj Breast Cancer. https://doi.org/10.1038/s41523-019-0111-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.